Seven People Infected During HIV Prevention Trial

Seven people reportedly contracted the human immunodeficiency virus (HIV) while participating in a clinical trial examining Viiv Healthcare’s Apretude (cabotegravir), an integrase inhibitor used in pre-exposure prophylaxis (PrEP) for the prevention of sexually transmitted HIV.

Viiv has not released a statement, but Raphael J. Landovitz, a principal investigator on the study at University of California, Los Angeles, confirmed that the infections were seen at his clinical site.

The FDA approved Apretude for pre-exposure prophylaxis in 2021.